Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Jul 25, 2023

SELL
$36.12 - $47.5 $2,492 - $3,277
-69 Reduced 1.19%
5,713 $228,000
Q1 2023

Apr 14, 2023

BUY
$35.53 - $43.38 $205,434 - $250,823
5,782 New
5,782 $235,000
Q3 2022

Oct 25, 2022

BUY
$51.24 - $58.89 $41,504 - $47,700
810 Added 20.56%
4,749 $253,000
Q2 2022

Aug 12, 2022

SELL
$51.49 - $81.64 $25,745 - $40,820
-500 Reduced 11.26%
3,939 $230,000
Q1 2022

May 11, 2022

BUY
$60.03 - $76.49 $266,473 - $339,539
4,439 New
4,439 $339,000
Q3 2021

Nov 02, 2021

SELL
$54.64 - $61.3 $205,391 - $230,426
-3,759 Closed
0 $0
Q2 2021

Aug 11, 2021

SELL
$59.18 - $69.99 $91,373 - $108,064
-1,544 Reduced 29.12%
3,759 $228,000
Q1 2021

May 14, 2021

BUY
$59.31 - $78.82 $72,595 - $96,475
1,224 Added 30.01%
5,303 $372,000
Q4 2020

Feb 12, 2021

SELL
$50.47 - $66.26 $15,292 - $20,076
-303 Reduced 6.91%
4,079 $244,000
Q3 2020

Nov 04, 2020

SELL
$51.97 - $63.0 $109,552 - $132,804
-2,108 Reduced 32.48%
4,382 $263,000
Q2 2020

Jul 17, 2020

SELL
$30.8 - $52.47 $10,995 - $18,731
-357 Reduced 5.21%
6,490 $341,000
Q1 2020

Apr 21, 2020

BUY
$28.4 - $50.7 $25,105 - $44,818
884 Added 14.82%
6,847 $230,000
Q4 2019

Feb 12, 2020

BUY
$36.31 - $46.83 $216,516 - $279,247
5,963 New
5,963 $270,000
Q3 2019

Nov 07, 2019

SELL
$35.66 - $44.99 $191,173 - $241,191
-5,361 Closed
0 $0
Q2 2019

Aug 06, 2019

BUY
$36.57 - $47.97 $196,051 - $257,167
5,361 New
5,361 $233,000
Q1 2019

May 06, 2019

SELL
$36.47 - $42.17 $204,304 - $236,236
-5,602 Closed
0 $0
Q4 2018

Feb 11, 2019

BUY
$41.31 - $52.16 $25,199 - $31,817
610 Added 12.22%
5,602 $241,000
Q3 2018

Nov 14, 2018

BUY
$32.85 - $52.0 $163,987 - $259,584
4,992 New
4,992 $245,000

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $892M
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.